Lawrence Mayer
32Patents
20h-index
32Co-inventors
85Inventor score
Filing activity: Nov 17, 1987 → Feb 11, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5595756A | Liposomal compositions for enhanced retention of bioactive agents | Human Necessities | 600 | Expired |
| US5077056A | Encapsulation of antineoplastic agents in liposomes | Emerging Cross-Sectional Technologies | 204 | Expired |
| US5543152A | Sphingosomes for enhanced drug delivery | Human Necessities | 187 | Expired |
| US5741516A | Sphingosomes for enhanced drug delivery | Human Necessities | 155 | Expired |
| US4975282A | Multilamellar liposomes having improved trapping efficiencies | Human Necessities | 126 | Expired |
| US5736155A | Encapsulation of antineoplastic agents in liposomes | Human Necessities | 101 | Expired |
| US5795589A | Liposomal antineoplastic agent compositions | Emerging Cross-Sectional Technologies | 80 | Expired |
| US5814335A | Sphingosomes for enhanced drug delivery | Human Necessities | 79 | Expired |
| US5409704A | Liposomes comprising aminoglycoside phosphates and methods of production and use | Emerging Cross-Sectional Technologies | 75 | Expired |
| US8022279B2 | Liposomal formulations of anthracycline agents and cytidine analogs | Emerging Cross-Sectional Technologies | 48 | Active |
| US7842676B2 | Fixed ratio drug combination treatments for solid tumors | Human Necessities | 47 | Active |
| US5616341A | High drug:lipid formulations of liposomal antineoplastic agents | Emerging Cross-Sectional Technologies | 46 | Expired |
| US8486924B2 | Taxane delivery system | Chemistry; Metallurgy | 44 | Active |
| US8092828B2 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders | Emerging Cross-Sectional Technologies | 42 | Active |
| US8518437B2 | Lipid carrier compositions with enhanced blood stability | Human Necessities | 39 | Active |
| US10028912B2 | Method of lyophilizing liposomes | Human Necessities | 38 | Active |
| US8431806B2 | Liposomal formulations of anthracycline agents and cytidine analogs | Emerging Cross-Sectional Technologies | 38 | Active |
| US7850990B2 | Compositions for delivery of drug combinations | Human Necessities | 37 | Active |
| US10058507B2 | Compositions for delivery of drug combinations | Human Necessities | 37 | Active |
| US10905775B2 | Particulate constructs for release of active agents | Human Necessities | 36 | Active |
| US6083530A | High drug:lipid formulations of liposomal-antineoplastic agents | Emerging Cross-Sectional Technologies | 17 | Expired |
| US5975578A | Portfolio and method of making the same | Emerging Cross-Sectional Technologies | 11 | Expired |
| US5744158A | Methods of treatment using high drug-lipid formulations of liposomal-antineoplastic agents | Emerging Cross-Sectional Technologies | 9 | Expired |
| US10166184B2 | Method of lyophilizing liposomes | Human Necessities | 4 | Active |
| US10927418B2 | Assays and methods for selecting a treatment regimen for a subject with leukemia | Chemistry; Metallurgy | 3 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.